



Steve Bloom was born in Kent in 1942 and received his undergraduate medical training at Cambridge University. His house officer, senior house officer and registrar posts were largely undertaken at The Middlesex Hospital where he also received his MRC Clinical Research Fellow training. He moved to the Royal Postgraduate Medical School at Hammersmith Hospital in 1974 where his roles have included Senior Lecturer (Consultant Physician), Reader in Medicine, Chairman of the Higher Degrees Committee and Academic Board, Professor of Medicine (Honorary Consultant Physician), Director of the Endocrinology Clinical Service and Deputy Director, Department of Medicine, Director of Chemical Pathology (renamed Metabolic Medicine and later Investigative Medicine), Chief of Clinical Service Chemical Pathology and Chief of Service Endocrinology and Diabetes. Having stepped down from his 10-year tenure as Head of Division of Investigative Science in 2007, Steve now holds the role of Head of Division of Diabetes, Endocrinology and Metabolism within Imperial College London and Clinical Director of the North West London Pathology Consortium within Imperial College NHS Trust.

His research work over the years falls into five related categories: endocrinology clinical research, physiology and pathology of gut hormones, control of insulin release and insulin resistance, role of neuropeptides in organ control and the role of neuropeptides in CNS regulation of appetite and related hypothalamic functions. He currently leads a research group investigating hypothalamic appetite control systems and gut hormones. This group's discovery that oxyntomodulin reduces appetite offers a potential new treatment for obesity and in 2005 Steve co-founded spin out company 'Thiakis Ltd' to commercialise these findings. In 2008 Wyeth Pharmaceuticals successfully acquired Thiakis for a reported £150 million.

He has published over 1000 papers (excluding review articles) in journals such as Nature, J Biol Chem, PNAS, JCI and NEJM. In the past Steve has been a member of the Main Scientific Board for AstraZeneca and advisory boards for Upjohn and Novartis.

In 2012 Professor Sir Steve Bloom was awarded a Knight Bachelor for Services to medical science and in 2013 was elected a Fellow of the Royal Society of London for Improving Natural Knowledge.